Novavax (NVAX)
(Delayed Data from NSDQ)
$15.03 USD
-0.22 (-1.44%)
Updated May 31, 2024 04:00 PM ET
After-Market: $15.04 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Novavax, Inc. [NVAX]
Reports for Purchase
Showing records 161 - 180 ( 296 total )
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Blink and You Might Miss NVX-CoV2373?s Rapid Progress; Reiterate Buy and $290 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
When Selecting NVX-CoV2373, We Think You?ve Chosen Wisely
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
A Definable Sustainable Commercial CoV Vaccine Opportunity Has Emerged; Raising Price Target to $132
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Fireside Chat Bolsters Our View of NVX-CoV2373?s Potential; Reiterate Buy With PT Raised to $101
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Experience Pays With CEPI Investment of up to $388M in the CoV Vaccine
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Rapid Progress Behind the Scenes Results in Accelerating Timeline of Coronavirus Vaccine Program;
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 Data Clearly Show NanoFlu is a Better Flu Vaccine.
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Keeping the NanoFlu Pivotal Phase 3 Readout on our Radar; Reit Buy and $17 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Vaccine Program Makes Important Advances; Reiterate Buy Rating and $17 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Tracking the Course of the Coronavirus Epidemic: KOL Conference Call Recap
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R